For instance, Rifaximin could alleviated visceral hypersensitivity, recovered intestinal barrier function, and inhibited low-grade inflammation in colon and ileum of PI-IBS mouse model via suppressing the expression of IL-17 and promoting the expression of the major tight junction protein occluding [16]. This evidence concerns the gene IL17A and irritable bowel syndrome.